Trial Profile
Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NanoCarrier
- 09 Feb 2023 This trial has been discontinued in Poland, according to European Clinical Trials Database record.
- 07 Jul 2022 This trial has been completed in Czech Republic and Croatia (End Date: 30 June 2022), according to European Clinical Trials Database record..
- 29 Jun 2022 This trial has been discontinued in Hungary (Global end date: 30 June 2022).